Characterization of Immune Response in Participants from a Posdinemab Study
Latest Information Update: 15 Sep 2025
At a glance
- Drugs Posdinemab (Primary)
- Indications Alzheimer's disease
- Focus Pharmacodynamics
- Acronyms NOPRODALZ0005
- Sponsors Janssen-Cilag
Most Recent Events
- 15 Sep 2025 New trial record